Varghese Edwin Hillary

Varghese Edwin Hillary

Auto-generated profile, based on publicly available information

Varghese Edwin Hillary

Department of Biosciences, Rajagiri College of Social Sciences, Cochin, 683 104, Kerala, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

22 February 2023 in Heliyon
Verified
Journal Article
Open access
VHVarghese Edwin Hillary
Varghese Edwin Hillary
Antony Ceasar StanislausAntony Ceasar Stanislaus
Antony Ceasar Stanislaus
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious and pathogenic virus that first appeared in late December 2019. This SARS-CoV-2 causes an infection of an acute respiratory disease called "coronavirus infectious disease-2019 (COVID-19). The World Health Organization (WHO) declared this SARS-CoV-2 outbreak a great pandemic on March 11, 2020. As of January 31, 2023, SARS-CoV-2 recorded more than 67 million cases and over 6 million deaths. Recently, novel mutated variants of SARS-CoV are also creating a serious health concern worldwide, and the future novel variant is still mysterious. As infection cases of SARS-CoV-2 are increasing daily, scientists are trying to combat the disease using numerous antiviral drugs and vaccines against SARS-CoV-2. To our knowledge, this is the first comprehensive review that summarized the dynamic nature of SARS-CoV-2 transmission, SARS-CoV-2 variants (a variant of concern and variant of interest), antiviral drugs and vaccines utilized against SARS-CoV-2 at a glance. Hopefully, this review will enable the researcher to gain knowledge on SARS-CoV-2 variants and vaccines, which will also pave the way to identify efficient novel vaccines against forthcoming SARS-CoV-2 strains.
1

5 January 2024 in Entomologia Experimentalis et Applicata
Verified
Journal Article
Closed access
VHV. Edwin Hillary
V. Edwin Hillary
Antony Ceasar StanislausAntony Ceasar Stanislaus
Antony Ceasar Stanislaus
SIS. Ignacimuthu
S. Ignacimuthu

1 January 2020 in Frontiers in Bioscience-Elite
Verified
Journal Article
Open access
SS. Ignacimuthu
S. Ignacimuthu
MSMamangam Subaraja
Mamangam Subaraja
DKDhanabalan Anantha Krishnan
Dhanabalan Anantha Krishnan
VHVarghese Edwin Hillary
Varghese Edwin Hillary
TRTharsius Raja William Raja
Tharsius Raja William Raja
MPMichael Gabriel Paulraj
Michael Gabriel Paulraj
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that causes memory and cognitive deficits. The present study was carried out to evaluate the protective effects of fucoidan in monocrotophos induced AD in Drosophila melanogaster. In silico studies showed that fucoidan exhibited binding energy of -9.3 kcal with proteins. Consistent with this, fucoidan, in a dose and time-dependent fashion, had inhibitory activity against cholinergic and monoamine-metabolized enzymes in vitro. Fucoidan inhibited the increase in total mRNA and protein in monocrotophos fed flies and prevented changes in biochemicals, neurochemicals and latency time of locomotor, learning and memory induced by monocrotophos. Together, the findings show that fucoidan serves a neuroprotective effect in Alzheimer’s disease model in D. melanogaster.

1 August 2024 in Nano-Structures & Nano-Objects
Verified
Journal Article
Closed access
MSM. Dayana Senthamarai
M. Dayana Senthamarai
VHV. Edwin Hillary
V. Edwin Hillary
MRM.R. Rajan
M.R. Rajan
Antony Ceasar StanislausAntony Ceasar Stanislaus
Antony Ceasar Stanislaus

15 March 2023 in Heliyon
Verified
Journal Article
Open access
SGSathiyabama Rajiv Gandhi
Sathiyabama Rajiv Gandhi
GGGopalsamy Rajiv Gandhi
Gopalsamy Rajiv Gandhi
PAPoovathumkal James Antony
Poovathumkal James Antony
VHVarghese Edwin Hillary
Varghese Edwin Hillary
SCStanislaus Antony Ceasar
Stanislaus Antony Ceasar
LQLucindo José Quintans-Júnior
Lucindo José Quintans-Júnior
The Miconia genus is traditionally used in folk medicine in Brazil and other tropical American countries and is represented by 282 species in this region. It is a multifaceted genus of medicinal plants widely used to treat rheumatoid arthritis (RA), pain, inflammatory diseases, and many more therapeutic applications. In the present study, we systematically identify and discuss the literature on in vivo and in vitro studies focusing on the therapeutic potentials and related molecular mechanisms of the Miconia genus. The review also assessed phytochemicals and their pharmacological properties and considered safety concerns related to the genus. Literature searches to identify studies on the Miconia genus were carried out through four main electronic databases, namely PubMed, Embase, Scopus, and Web of Science limited to Medical Subjects Headings (MeSH) and Descriptores en Ciencias de la Salud (DCS) (Health Sciences Descriptors) to identify studies published up to December 2022. The relevant information about the genus was gathered using the keywords 'Miconia', 'biological activities', 'therapeutic mechanisms', 'animal model, 'cell-line model', 'antinociceptive', 'hyperalgesia', 'anti-inflammatory', and 'inflammation'. The therapeutic potentials and mechanisms of action of 14 species from genus Miconia were examined in 18 in vitro studies and included their anti-inflammatory, anticancer, analgesic, antibacterial, cytotoxic, mutagenic, antioxidant, anti-leishmanial, antinociceptive, schistosomicidal, and anti-osteoarthritis potentials, and in eight in vivo studies, assessing their analgesic, antioxidant, antinociceptive, and anti-osteoarthritis activities. Some of the main related molecular mechanisms identified are the modulation of cytokines such as IL-1β, IL-6, and TNF-α, as well as the inhibition of inflammatory mediators and prostaglandin synthesis. The limited number of studies showed that commonly available species from the genus Miconia are safe for consumption. Miconia albicans Sw.Triana and Miconia rubiginosa (Bonpl.) DC was the most frequently used species and showed significant efficacy and potential for developing safe drugs to treat pain and inflammation.